APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dementia and Alzheimer’s Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Dementia and Alzheimer’s Disease Treatment Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchDementia and Alzheimer’s Disease Treatment Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Dementia and Alzheimer’s Disease Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Dementia and Alzheimer’s Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dementia and Alzheimer’s Disease Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Dementia and Alzheimer’s Disease Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Dementia and Alzheimer’s Disease Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Dementia and Alzheimer’s Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Dementia and Alzheimer’s Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Dementia and Alzheimer’s Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Dementia and Alzheimer’s Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Dementia and Alzheimer’s Disease Treatment include Novartis, Eli Lilly and Company, Pfizer, Inc., AbbVie Inc., AstraZeneca, INmuneBIO, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd. and Biogen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Dementia and Alzheimer’s Disease Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Dementia and Alzheimer’s Disease Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Dementia and Alzheimer’s Disease Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dementia and Alzheimer’s Disease Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Dementia and Alzheimer’s Disease Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Dementia and Alzheimer’s Disease Treatment revenue, projected growth trends, production technology, application and end-user industry.

Dementia and Alzheimer’s Disease Treatment Segment by Company

Novartis

Eli Lilly and Company

Pfizer, Inc.

AbbVie Inc.

AstraZeneca

INmuneBIO

F. Hoffmann-La Roche Ltd.

Eisai Co., Ltd.

Biogen

Allergan plc

Dementia and Alzheimer’s Disease Treatment Segment by Type

Combination Drugs

Memantine

Cholinesterase Inhibitors

Dementia and Alzheimer’s Disease Treatment Segment by Application

Hospital

Clinic

Dementia and Alzheimer’s Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dementia and Alzheimer’s Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dementia and Alzheimer’s Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dementia and Alzheimer’s Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Dementia and Alzheimer’s Disease Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Dementia and Alzheimer’s Disease Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dementia and Alzheimer’s Disease Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Dementia and Alzheimer’s Disease Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Combination Drugs Major Player Table 3. Memantine Major Player Table 4. Cholinesterase Inhibitors Major Player Table 5. Global Dementia and Alzheimer’s Disease Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Dementia and Alzheimer’s Disease Treatment Industry Trends Table 9. Dementia and Alzheimer’s Disease Treatment Industry Drivers Table 10. Dementia and Alzheimer’s Disease Treatment Industry Opportunities and Challenges Table 11. Dementia and Alzheimer’s Disease Treatment Industry Restraints Table 12. Global Dementia and Alzheimer’s Disease Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Dementia and Alzheimer’s Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Dementia and Alzheimer’s Disease Treatment Market Share by Region (2021-2026) Table 15. Global Dementia and Alzheimer’s Disease Treatment Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Dementia and Alzheimer’s Disease Treatment Market Share by Region (2027-2032) Table 17. Global Dementia and Alzheimer’s Disease Treatment Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Players (2021-2026) Table 19. Global Dementia and Alzheimer’s Disease Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Dementia and Alzheimer’s Disease Treatment Key Players Headquarters & Area Served Table 21. Global Dementia and Alzheimer’s Disease Treatment Players, Product Type & Application Table 22. Global Dementia and Alzheimer’s Disease Treatment Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Dementia and Alzheimer’s Disease Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Dementia and Alzheimer’s Disease Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Dementia and Alzheimer’s Disease Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Application (2027-2032) Table 35. Novartis Company Information Table 36. Novartis Business Overview Table 37. Novartis Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Novartis Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 39. Novartis Recent Development Table 40. Eli Lilly and Company Company Information Table 41. Eli Lilly and Company Business Overview Table 42. Eli Lilly and Company Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Eli Lilly and Company Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 44. Eli Lilly and Company Recent Development Table 45. Pfizer, Inc. Company Information Table 46. Pfizer, Inc. Business Overview Table 47. Pfizer, Inc. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Pfizer, Inc. Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 49. Pfizer, Inc. Recent Development Table 50. AbbVie Inc. Company Information Table 51. AbbVie Inc. Business Overview Table 52. AbbVie Inc. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. AbbVie Inc. Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 54. AbbVie Inc. Recent Development Table 55. AstraZeneca Company Information Table 56. AstraZeneca Business Overview Table 57. AstraZeneca Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AstraZeneca Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 59. AstraZeneca Recent Development Table 60. INmuneBIO Company Information Table 61. INmuneBIO Business Overview Table 62. INmuneBIO Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. INmuneBIO Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 64. INmuneBIO Recent Development Table 65. F. Hoffmann-La Roche Ltd. Company Information Table 66. F. Hoffmann-La Roche Ltd. Business Overview Table 67. F. Hoffmann-La Roche Ltd. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. F. Hoffmann-La Roche Ltd. Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 69. F. Hoffmann-La Roche Ltd. Recent Development Table 70. Eisai Co., Ltd. Company Information Table 71. Eisai Co., Ltd. Business Overview Table 72. Eisai Co., Ltd. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Eisai Co., Ltd. Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 74. Eisai Co., Ltd. Recent Development Table 75. Biogen Company Information Table 76. Biogen Business Overview Table 77. Biogen Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Biogen Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 79. Biogen Recent Development Table 80. Allergan plc Company Information Table 81. Allergan plc Business Overview Table 82. Allergan plc Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Allergan plc Dementia and Alzheimer’s Disease Treatment Product Portfolio Table 84. Allergan plc Recent Development Table 85. North America Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Dementia and Alzheimer’s Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 99. China Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 100. China Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 101. China Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. China Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Dementia and Alzheimer’s Disease Treatment Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Dementia and Alzheimer’s Disease Treatment Image Figure 2. Global Dementia and Alzheimer’s Disease Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dementia and Alzheimer’s Disease Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Combination Drugs Image Figure 5. Memantine Image Figure 6. Cholinesterase Inhibitors Image Figure 7. Global Dementia and Alzheimer’s Disease Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Dementia and Alzheimer’s Disease Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Global Dementia and Alzheimer’s Disease Treatment Market Size (US$ Million) & (2021-2032) Figure 12. Global Dementia and Alzheimer’s Disease Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Dementia and Alzheimer’s Disease Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Dementia and Alzheimer’s Disease Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Type (2021-2032) Figure 19. Global Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032) Figure 24. North America Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032) Figure 25. North America Dementia and Alzheimer’s Disease Treatment Revenue Share by Country (2021-2032) Figure 26. United States Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032) Figure 31. Europe Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032) Figure 32. Europe Dementia and Alzheimer’s Disease Treatment Revenue Share by Country (2021-2032) Figure 33. Germany Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032) Figure 43. China Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032) Figure 44. Asia Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032) Figure 46. Asia Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Dementia and Alzheimer’s Disease Treatment Revenue Share by Region (2021-2032) Figure 48. Japan Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032) Figure 56. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032) Figure 57. SAMEA Dementia and Alzheimer’s Disease Treatment Revenue Share by Country (2021-2032) Figure 58. Brazil Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Dementia and Alzheimer’s Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Drugs
  • Memantine
  • Cholinesterase Inhibitors
Applications
  • Hospital
  • Clinic
Companies covered
  • Novartis
  • Eli Lilly and Company
  • Pfizer, Inc.
  • AbbVie Inc.
  • AstraZeneca
  • INmuneBIO
  • F. Hoffmann-La Roche Ltd.
  • Eisai Co., Ltd.
  • Biogen
  • Allergan plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Dementia and Alzheimer’s Disease Treatment Market by Type
  3. 1.2.1 Global Dementia and Alzheimer’s Disease Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Combination Drugs
  5. 1.2.3 Memantine
  6. 1.2.4 Cholinesterase Inhibitors
  7. 1.3 Dementia and Alzheimer’s Disease Treatment Market by Application
  8. 1.3.1 Global Dementia and Alzheimer’s Disease Treatment Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Dementia and Alzheimer’s Disease Treatment Market Dynamics
  1. 2.1 Dementia and Alzheimer’s Disease Treatment Industry Trends
  2. 2.2 Dementia and Alzheimer’s Disease Treatment Industry Drivers
  3. 2.3 Dementia and Alzheimer’s Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Dementia and Alzheimer’s Disease Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Dementia and Alzheimer’s Disease Treatment Market Perspective (2021-2032)
  2. 3.2 Global Dementia and Alzheimer’s Disease Treatment Growth Trends by Region
  3. 3.2.1 Global Dementia and Alzheimer’s Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Dementia and Alzheimer’s Disease Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Dementia and Alzheimer’s Disease Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Dementia and Alzheimer’s Disease Treatment Revenue by Players
  2. 4.1.1 Global Dementia and Alzheimer’s Disease Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Dementia and Alzheimer’s Disease Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Dementia and Alzheimer’s Disease Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Dementia and Alzheimer’s Disease Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Dementia and Alzheimer’s Disease Treatment Players, Product Type & Application
  8. 4.5 Global Dementia and Alzheimer’s Disease Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Dementia and Alzheimer’s Disease Treatment Market CR5 and HHI
  11. 4.6.3 2025 Dementia and Alzheimer’s Disease Treatment Tier 1, Tier 2, and Tier 3
5 Dementia and Alzheimer’s Disease Treatment Market Size by Type
  1. 5.1 Global Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Type (2021-2032)
6 Dementia and Alzheimer’s Disease Treatment Market Size by Application
  1. 6.1 Global Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Dementia and Alzheimer’s Disease Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Dementia and Alzheimer’s Disease Treatment Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Eli Lilly and Company
  8. 7.2.1 Eli Lilly and Company Company Information
  9. 7.2.2 Eli Lilly and Company Business Overview
  10. 7.2.3 Eli Lilly and Company Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly and Company Dementia and Alzheimer’s Disease Treatment Product Portfolio
  12. 7.2.5 Eli Lilly and Company Recent Developments
  13. 7.3 Pfizer, Inc.
  14. 7.3.1 Pfizer, Inc. Company Information
  15. 7.3.2 Pfizer, Inc. Business Overview
  16. 7.3.3 Pfizer, Inc. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer, Inc. Dementia and Alzheimer’s Disease Treatment Product Portfolio
  18. 7.3.5 Pfizer, Inc. Recent Developments
  19. 7.4 AbbVie Inc.
  20. 7.4.1 AbbVie Inc. Company Information
  21. 7.4.2 AbbVie Inc. Business Overview
  22. 7.4.3 AbbVie Inc. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AbbVie Inc. Dementia and Alzheimer’s Disease Treatment Product Portfolio
  24. 7.4.5 AbbVie Inc. Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Dementia and Alzheimer’s Disease Treatment Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 INmuneBIO
  32. 7.6.1 INmuneBIO Company Information
  33. 7.6.2 INmuneBIO Business Overview
  34. 7.6.3 INmuneBIO Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 INmuneBIO Dementia and Alzheimer’s Disease Treatment Product Portfolio
  36. 7.6.5 INmuneBIO Recent Developments
  37. 7.7 F. Hoffmann-La Roche Ltd.
  38. 7.7.1 F. Hoffmann-La Roche Ltd. Company Information
  39. 7.7.2 F. Hoffmann-La Roche Ltd. Business Overview
  40. 7.7.3 F. Hoffmann-La Roche Ltd. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 F. Hoffmann-La Roche Ltd. Dementia and Alzheimer’s Disease Treatment Product Portfolio
  42. 7.7.5 F. Hoffmann-La Roche Ltd. Recent Developments
  43. 7.8 Eisai Co., Ltd.
  44. 7.8.1 Eisai Co., Ltd. Company Information
  45. 7.8.2 Eisai Co., Ltd. Business Overview
  46. 7.8.3 Eisai Co., Ltd. Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eisai Co., Ltd. Dementia and Alzheimer’s Disease Treatment Product Portfolio
  48. 7.8.5 Eisai Co., Ltd. Recent Developments
  49. 7.9 Biogen
  50. 7.9.1 Biogen Company Information
  51. 7.9.2 Biogen Business Overview
  52. 7.9.3 Biogen Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Biogen Dementia and Alzheimer’s Disease Treatment Product Portfolio
  54. 7.9.5 Biogen Recent Developments
  55. 7.10 Allergan plc
  56. 7.10.1 Allergan plc Company Information
  57. 7.10.2 Allergan plc Business Overview
  58. 7.10.3 Allergan plc Dementia and Alzheimer’s Disease Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Allergan plc Dementia and Alzheimer’s Disease Treatment Product Portfolio
  60. 7.10.5 Allergan plc Recent Developments
8 North America
  1. 8.1 North America Dementia and Alzheimer’s Disease Treatment Revenue (2021-2032)
  2. 8.2 North America Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Dementia and Alzheimer’s Disease Treatment Revenue by Country
  11. 8.6.1 North America Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Dementia and Alzheimer’s Disease Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Dementia and Alzheimer’s Disease Treatment Revenue (2021-2032)
  2. 9.2 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country
  11. 9.6.1 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Dementia and Alzheimer’s Disease Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Dementia and Alzheimer’s Disease Treatment Revenue (2021-2032)
  2. 10.2 China Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032)
  5. 10.3 China Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032)
  9. 10.5 China Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Dementia and Alzheimer’s Disease Treatment Revenue (2021-2032)
  2. 11.2 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Country
  11. 11.6.1 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Dementia and Alzheimer’s Disease Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country
  11. 12.6.1 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Dementia and Alzheimer’s Disease Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst